8 reasons why you can use esomeprazole Review article
Article Sidebar
Published:
Dec 31, 2023
Keywords:
proton pump inhibitors, PPI, esomeprasole, gastroesophageal reflux disease, acid-dependent diseases
Main Article Content
Abstract
Over two decades of use of proton pump inhibitors in the treatment of acid-dependent diseases have resulted in therapeutic success on the one hand, but still insufficient effectiveness on the other. The introduction of esomeprazole to the pharmaceutical market resulted in an increase in the percentage of effective treatment while maintaining a good patient safety profile compared to other drugs of this group.
Article Details
How to Cite
Waśko-Czopnik, D. (2023). 8 reasons why you can use esomeprazole. Medycyna Faktow (J EBM), 16(4(61), 335-340. https://doi.org/10.24292/01.MF.0423.07
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Woroń J. Blaski i cienie powszechnie stosowanych inhibitorów pompy protonowej. Medycyna po Dyplomie. 2023; 3.
2. Lind T, Rydberg L, Kylebäck A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000; 14: 861-7.
3. Castell DO, Kahrilas JP, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002; 97(3): 575-83.
4. Labenz J, Armstrong D, Lauritsen K et al.; the EXPO study. A randomised, comparative study of esomeprazole 40 mg vs pantoprazole 40 mg for healing erosive esophagitis. Aliment Pharmacol Ther. 2005; 21: 739-46.
5. Wocial T. Czy jest nam potrzebny esomeprazol? Gastroenterologia Kliniczna. 2010; 2: 56-63.
6. Celebi A, Aydin D, Kocaman O et al. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol. 2016; 27(5): 408-14.
7. Kirchheiner J, Fur U, Klotz U et al. Relative potency of proton-pomp inhibitors – comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009; 65: 19-31.
8. Wocial T. Esomeprazol – skuteczna ochrona przewodu pokarmowego w trakcie leczenia niesteroidowymi lekami przeciwzapalnymi. Medycyna Faktów. 2015; 2(27): 74-80.
9. Saini SD, Fendrick AM, Scheiman JM et al. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor cotherapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther. 2011; 34: 243-51.
10. Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021; 160: 1831-11.
11. Vallve M, Vergara M, Gisbert JP et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther. 2002; 16: 1149-56.
12. Daniluk J. Helicobacter pylori eradication – the most common mistakes. Lekarz POZ. 2021; 7(6).
13. Malfertheiner P, Megraud F, Rokkas T et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; 71: 1724-62.
14. Uchiyama T, Higurashi T, Kuriyama H et al. Oral esomeprazole vs injectable omeprazole for the prevention of hemorrhage after endoscopic submucosal dissection. World J Gastrointest Endosc. 2017; 9(10): 514-20.
15. Hoogendoorn RJ, Groeneveld L, Kwee JA. Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease an observational, multicentre study. Clin Drug Investig. 2009; 29(12): 803-10.
16. Charakterystyka produktu leczniczego RO/H/0130/001-002/IB/033; RMS approval date: 24.11.2023 r.
17. Orr CW. Night-time gastro-oesophageal reflux disease: prevelance, hazards and management. Eur J Gastroenterol Hepatol. 2005; 17(1): 113-20.
2. Lind T, Rydberg L, Kylebäck A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000; 14: 861-7.
3. Castell DO, Kahrilas JP, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002; 97(3): 575-83.
4. Labenz J, Armstrong D, Lauritsen K et al.; the EXPO study. A randomised, comparative study of esomeprazole 40 mg vs pantoprazole 40 mg for healing erosive esophagitis. Aliment Pharmacol Ther. 2005; 21: 739-46.
5. Wocial T. Czy jest nam potrzebny esomeprazol? Gastroenterologia Kliniczna. 2010; 2: 56-63.
6. Celebi A, Aydin D, Kocaman O et al. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol. 2016; 27(5): 408-14.
7. Kirchheiner J, Fur U, Klotz U et al. Relative potency of proton-pomp inhibitors – comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009; 65: 19-31.
8. Wocial T. Esomeprazol – skuteczna ochrona przewodu pokarmowego w trakcie leczenia niesteroidowymi lekami przeciwzapalnymi. Medycyna Faktów. 2015; 2(27): 74-80.
9. Saini SD, Fendrick AM, Scheiman JM et al. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor cotherapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther. 2011; 34: 243-51.
10. Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021; 160: 1831-11.
11. Vallve M, Vergara M, Gisbert JP et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther. 2002; 16: 1149-56.
12. Daniluk J. Helicobacter pylori eradication – the most common mistakes. Lekarz POZ. 2021; 7(6).
13. Malfertheiner P, Megraud F, Rokkas T et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; 71: 1724-62.
14. Uchiyama T, Higurashi T, Kuriyama H et al. Oral esomeprazole vs injectable omeprazole for the prevention of hemorrhage after endoscopic submucosal dissection. World J Gastrointest Endosc. 2017; 9(10): 514-20.
15. Hoogendoorn RJ, Groeneveld L, Kwee JA. Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease an observational, multicentre study. Clin Drug Investig. 2009; 29(12): 803-10.
16. Charakterystyka produktu leczniczego RO/H/0130/001-002/IB/033; RMS approval date: 24.11.2023 r.
17. Orr CW. Night-time gastro-oesophageal reflux disease: prevelance, hazards and management. Eur J Gastroenterol Hepatol. 2005; 17(1): 113-20.